Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 10:58 AM
Ignite Modification Date:
2025-12-26 @ 10:58 AM
NCT ID:
NCT07249606
Eligibility Criteria:
Inclusion Criteria:
1. Patients aged 18 years or older.
2. Patients diagnosed with primary or post-polycythemia vera/post-essential thrombocythemia myelofibrosis start treatment with MMB according to clinical practice from AIFA authorization.
3. Patients with palpable splenomegaly at baseline of momelotinib treatment.
4. Informed consent signed, if applicable.
Exclusion Criteria:
1. Diagnosis of MPN, unclassifiable, myelodysplastic/myeloproliferative neoplasms, myelodysplastic syndromes, essential thrombocythemia, polycythemia vera.
2. Accelerated/blast phase of MF.
3. Patients with platelets \<20 x10(9)/L at baseline of MMB treatment.
4. Patients JAK inhibitors-exposed for other diseases apart from MF.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07249606
Study Brief:
Protocol Section:
NCT07249606